Quick Answer
OCULAR THERAPEUTIX, INC reported Diluted EPS of $1.42 per share (loss) for fiscal year 2025.
OCULAR THERAPEUTIX, INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.42 | -16.4% |
| 2024 | -$1.22 | -19.6% |
| 2023 | -$1.02 | -5.2% |
| 2022 | -$0.97 | +1.0% |
| 2021 | -$0.98 | +61.7% |
| 2020 | -$2.56 | -34.0% |
| 2019 | -$1.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.38 | -72.7% | +2.6% |
| June 30, 2025 | -$0.39 | -50.0% | -2.6% |
| March 31, 2025 | -$0.38 | +22.4% | -72.7% |
| September 30, 2024 | -$0.22 | +12.0% | +15.4% |
| June 30, 2024 | -$0.26 | +0.0% | +46.9% |
| March 31, 2024 | -$0.49 | -25.6% | -96.0% |
| September 30, 2023 | -$0.25 | +19.4% | +3.8% |
| June 30, 2023 | -$0.26 | -4.0% | +33.3% |
- OCULAR THERAPEUTIX, INC showed a decrease of -16.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, OCULAR THERAPEUTIX, INC’s diluted eps has grown by 25.7% (from $1.91 per share (loss) to $1.42 per share (loss)).
- The most recent figure is from OCULAR THERAPEUTIX, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: